Second Opinion: ASH 2020 Takeaways for Myelofibrosis

Dr. Ruben Mesa and Dr. Aaron Gerds discuss the current landscape of myelofibrosis and key takeaways from the 2020 ASH Annual Meeting and Exposition in this rare cancer. They also provide insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.